News | January 20, 2015

PotentiaMED Advisor Highlights Problems with Cancer Clinical Trials

Poor representative patient selection, exclusion of mitigating factors among issues to address

January 20, 2015 — The validity of randomized clinical trials in cancer has recently been called into question as many healthcare professionals are decrying the “experimerical” nature of these studies.

Jay F. Piccirillo, M.D., FACS, medical advisor for PotentiaMED, said, “The very nature of these studies is biased because they are often sponsored by pharmaceutical and device companies who have a vested interest in ensuring the studies have a positive outcome.”

 Piccirillo outlines the reasons randomized clinical trials are problematic:

  • Randomized clinical trials enroll younger and less racially diverse patients of the cancer population. “We know that roughly 53 percent of cancer patients are over the age of 65,” said Piccirillo, “Yet less than 33 percent of patients in the study are in this age group. Hence, we are getting data that is based on people who are much younger than the majority of our patients. Additionally, most of the people studied are white, meaning that we don’t have much data on people of color.”
  • Randomized clinical trials don’t consider comorbidity. “We have a saying in cancer treatment: ‘Sicker people die sooner,’” said Piccirillo. “This means that cancer patients with coexisting lung disease, heart disease, diabetes or other illnesses are less likely to improve with treatment and more likely to succumb quicker than cancer patients with less severe comorbidity. However, randomized clinical trials often exclude patients with comorbid ailments and so the results are not applicable to a large number of cancer patients.”
  • Randomized clinical trials don’t consider quality of life. “Randomized clinical trials seek ‘objective’ markers such as survival and tumor recurrence rates,” said Piccirillo, “These are important endpoints, however, patients increasingly also want information on quality of life and this important data simply isn’t available through clinical trials.”
  • Randomized clinical trials aren't publicized equally. “It is an inescapable truth that many of these trials are performed by companies who have a vested interest in the outcome,” said Piccirillo. “As such, they only tend to submit for publication and publicize positive findings. In fact, one study of selective publication bias found that 97 oercent (37 of 38) of positive trials were published while only 33 percent (8 of 24) of negative trials were published. This means that clinicians and patients who review the published medical literature receive a biased impression of treatment effectiveness.

 

“The reality is that only four percent of adults with cancer are involved in randomized clinical trials, yet healthcare professionals are using this information to determine the treatment for the other 96 percent of the population,” said Piccirillo. 

PotentiaMED was founded in 2009 with the goal of collecting and supplying invaluable treatment information for patients, doctors, hospitals, insurance providers, medical technology, and insurance providers. The PotentiaMED database offers patients all the data they need at their fingertips, from life expectancy to side effects to quality of life to future risk.

For more information: www.potentiamed.com

Related Content

Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
Advaxis Immunotherapy Offers Potential Combo Treatment for Anal Cancer
News | Radiation Therapy | January 26, 2018
January 26, 2018 — Advaxis Inc.
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
Age Impacts Post-treatment Mortality for Early-stage Lung Cancer Patients

Image courtesy of Henri Becquerel Cancer Center

News | Stereotactic Body Radiation Therapy (SBRT) | January 24, 2018
A University of Colorado Cancer Center study published in the Journal of Clinical Oncology explores mortality in the...
Brain Imaging Predicts Language Learning in Deaf Children
News | Magnetic Resonance Imaging (MRI) | January 23, 2018
January 23, 2018 – In a new international collaborative...
Overlay Init